-
Santhera Announces Preliminary 2022 Half-year Financial Results Ahead of Full Report Publication by End of October
-
Santhera Reports 2021 Annual Results
-
Santhera Announces Improved Liquidity Position
-
Santhera and ReveraGen Announce Successful FDA Pre-NDA Meeting for Vamorolone in Duchenne Muscular Dystrophy
-
Santhera Announces First Half-Year 2021 Financial Results and Updates on Corporate Progress
-
Santhera Secures CHF 45 Million in Funding and Announces Preliminary First Half-Year 2021 Financial Results
-
Santhera Reports 2020 Annual Results
-
Santhera Calls Extraordinary General Meeting to Seek Approval for Proposed Strengthening of Capital Structure
-
Santhera Announces Corporate Update and Proposal to Strengthen Capital Structure
-
Santhera Implements Reorganization and Secures Financing to Advance Vamorolone to Pivotal Read-out in Duchenne Muscular Dystrophy
-
Santhera Announces Financial Results for the First Half-Year 2020 and Updates on Corporate Progress
-
Santhera Announces Financial Results for the First Half-Year 2020 and Updates on Corporate Progress
-
Santhera Closes First Tranche of Financing Transaction
-
Santhera Completes Capital Increase for Financing Arrangements
-
Santhera Receives Financing Commitment of up to CHF 20 Million from Fund Managed by Highbridge Capital Management

